NNVC – NanoViricides Inc
NanoViricides, Inc.NNVC
$1.54Name : NanoViricides, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $24,750,880.00
EPSttm : -0.69
NanoViricides, Inc.
$1.54
3.36%$0.05Float Short %
0.45
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
EPS Last/This Y
0.13
EPS This/Next Y
0.57
Price
1.53
Target Price
6.5
Analyst Recom
1
Performance Q
21.26
Relative Volume
0.57
Beta
0.92
Ticker: NNVC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-08 | NNVC | 1.4192 | 0.02 | 0.00 | 2301 |
| 2025-05-09 | NNVC | 1.347 | 0.01 | 0.00 | 2288 |
| 2025-05-12 | NNVC | 1.27 | 0.01 | 0.00 | 2292 |
| 2025-05-13 | NNVC | 1.2561 | 0.01 | 0.00 | 2292 |
| 2025-05-14 | NNVC | 1.26 | 0.01 | 0.00 | 2295 |
| 2025-05-15 | NNVC | 1.29 | 0.01 | 0.00 | 2296 |
| 2025-05-16 | NNVC | 1.42 | 0.01 | 0.00 | 2456 |
| 2025-05-19 | NNVC | 1.455 | 0.01 | 0.05 | 2096 |
| 2025-05-20 | NNVC | 1.55 | 0.01 | 0.00 | 2098 |
| 2025-05-21 | NNVC | 1.4301 | 0.01 | 0.00 | 2250 |
| 2025-05-22 | NNVC | 1.49 | 0.01 | 0.00 | 2249 |
| 2025-05-23 | NNVC | 1.779 | 0.01 | 0.33 | 2268 |
| 2025-05-27 | NNVC | 1.695 | 0.09 | 0.00 | 2917 |
| 2025-05-28 | NNVC | 1.67 | 0.08 | 0.15 | 3013 |
| 2025-05-29 | NNVC | 1.57 | 0.08 | 0.00 | 3077 |
| 2025-05-30 | NNVC | 1.51 | 0.08 | 0.05 | 3082 |
| 2025-06-02 | NNVC | 1.52 | 0.08 | 0.00 | 3219 |
| 2025-06-03 | NNVC | 1.495 | 0.08 | 0.00 | 3238 |
| 2025-06-04 | NNVC | 1.57 | 0.08 | 0.00 | 3287 |
| 2025-06-05 | NNVC | 1.5 | 0.07 | 0.00 | 3488 |
| 2025-06-06 | NNVC | 1.53 | 0.07 | 0.00 | 3519 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-08 | NNVC | 1.43 | - | - | -0.57 |
| 2025-05-09 | NNVC | 1.32 | - | - | -0.57 |
| 2025-05-12 | NNVC | 1.28 | - | - | -0.57 |
| 2025-05-13 | NNVC | 1.25 | - | - | -0.57 |
| 2025-05-14 | NNVC | 1.24 | - | - | -0.57 |
| 2025-05-15 | NNVC | 1.29 | - | - | -0.57 |
| 2025-05-16 | NNVC | 1.41 | - | - | -0.57 |
| 2025-05-19 | NNVC | 1.46 | - | - | -0.57 |
| 2025-05-20 | NNVC | 1.56 | - | - | -0.57 |
| 2025-05-21 | NNVC | 1.44 | - | - | -0.57 |
| 2025-05-22 | NNVC | 1.47 | - | - | -0.57 |
| 2025-05-23 | NNVC | 1.78 | - | - | -0.57 |
| 2025-05-27 | NNVC | 1.71 | - | - | -0.57 |
| 2025-05-28 | NNVC | 1.59 | - | - | -0.57 |
| 2025-05-29 | NNVC | 1.57 | - | - | -0.57 |
| 2025-05-30 | NNVC | 1.52 | - | - | -0.57 |
| 2025-06-02 | NNVC | 1.54 | - | - | -0.57 |
| 2025-06-03 | NNVC | 1.47 | - | - | -0.57 |
| 2025-06-04 | NNVC | 1.57 | - | - | -0.57 |
| 2025-06-05 | NNVC | 1.49 | - | - | -0.57 |
| 2025-06-06 | NNVC | 1.53 | - | - | -0.57 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-08 | NNVC | 0.00 | 14.27 | 2.20 |
| 2025-05-09 | NNVC | 0.00 | 14.27 | 2.20 |
| 2025-05-12 | NNVC | 0.00 | 14.27 | 0.87 |
| 2025-05-13 | NNVC | 0.00 | 14.27 | 0.87 |
| 2025-05-14 | NNVC | 0.00 | 14.27 | 0.87 |
| 2025-05-15 | NNVC | 0.00 | 14.27 | 0.87 |
| 2025-05-16 | NNVC | 0.00 | 14.27 | 0.87 |
| 2025-05-19 | NNVC | 0.00 | 9.74 | 0.84 |
| 2025-05-20 | NNVC | 0.00 | 9.74 | 0.84 |
| 2025-05-21 | NNVC | 0.00 | 9.74 | 0.84 |
| 2025-05-22 | NNVC | 0.00 | 9.74 | 0.84 |
| 2025-05-23 | NNVC | 0.00 | 9.74 | 0.84 |
| 2025-05-27 | NNVC | 0.00 | 2.04 | 0.84 |
| 2025-05-28 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-05-29 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-05-30 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-06-02 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-06-03 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-06-04 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-06-05 | NNVC | 0.00 | 2.04 | 0.45 |
| 2025-06-06 | NNVC | 0.00 | 2.04 | 0.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
2.04
Beta
0.92
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
Sentiment Score
8
Actual DrawDown %
84.7
Max Drawdown 5-Year %
-88.6
Target Price
6.5
P/E
Forward P/E
PEG
P/S
P/B
2.8
P/Free Cash Flow
EPS
-0.7
Average EPS Est. Cur. Y
-0.57
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.57
Return on Equity vs Sector %
-134.2
Return on Equity vs Industry %
-116.2
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-0.57
EBIT Estimation
NanoViricides, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 7
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
stock quote shares NNVC – NanoViricides Inc Stock Price stock today
news today NNVC – NanoViricides Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NNVC – NanoViricides Inc yahoo finance google finance
stock history NNVC – NanoViricides Inc invest stock market
stock prices NNVC premarket after hours
ticker NNVC fair value insiders trading